This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synchrony (SYF) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Synchrony (SYF) delivered earnings and revenue surprises of 0.68% and 2.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma (RPRX) Surges 5.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Royalty Pharma (RPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Royalty Pharma (RPRX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 5.80% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Aug 12, 2021
by Zacks Equity Research
Companies In The News Are: WEN, HAE, RPRX, BLI
Royalty Pharma (RPRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.43% and 0.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Royalty Pharma (RPRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Constellation (CNST) Surges on Takeover Deal With MorphoSys
by Zacks Equity Research
Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SYF or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYF vs. RPRX: Which Stock Is the Better Value Option?
SYF vs. RPRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYF vs. RPRX: Which Stock Is the Better Value Option?
CIXX or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CIXX vs. RPRX: Which Stock Is the Better Value Option?
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?
by Zacks Equity Research
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
by Zacks Equity Research
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
What's in the Cards for Repros (RPRX) This Earnings Season?
by Zacks Equity Research
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Repros' Proellex Stays on Partial Clinical Hold, Shares Fall
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
What's in the Cards for Repros (RPRX) this Earnings Season?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Repros' Proellex Continues to be Under Partial Clinical Hold
by Zacks Equity Research
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Repros to Meet with the FDA for Phase III Proellex Program
by Zacks Equity Research
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.